Roche breast cancer pill cuts risk of disease recurrence by 30% in trial
LONDON, Dec 10 () - Roche said on Wednesday its experimental oral drug giredestrant reduced the risk of breast cancer recurrence by 30% compared with standard endocrine therapy, in what it said marked the first big advance in hormonal treatment for the disease in over 20 years. The Swiss drugmaker said detailed results from the phase III lidERA trial showed at three years, 92.